Modafinil (Provigil, Modalert)

Modafinil (brand names Provigil, Modalert) is a eugeroic, a wakefulness-promoting agent. The term matters because it deliberately sets the substance apart from the classic stimulant class: modafinil is neither structurally nor pharmacologically an amphetamine derivative. Clinically it is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnea and shift work sleep disorder.

The practical difference from a stimulant is best described like this: modafinil does not create drive, it removes tiredness. The subjective state is closer to "not tired" than "wired", without the marked euphoria, the rebound and the appetite collapse that typically come with amphetamines.

This information is for research and educational purposes only. No medical advice.

The mechanism is still not fully resolved, but two layers are well documented. First, modafinil inhibits the dopamine transporter (DAT) and thereby raises extracellular dopamine. The PET work by Volkow and colleagues (JAMA 2009) showed in humans that 200mg and 400mg occupy striatal dopamine transporters substantially and increase dopamine in the nucleus accumbens. The decisive difference from amphetamines: modafinil only blocks reuptake, it does not actively drive dopamine out of storage vesicles.

Second, modafinil acts indirectly on the wake systems of the hypothalamus - orexinergic and histaminergic pathways are activated, cortical catecholamines rise, GABA levels fall. Those are precisely the circuits governing the sleep-wake cycle, not the general drive systems. Hence the quiet effect profile.

• Modafinil (eugeroic): pure reuptake inhibition at DAT plus orexinergic-histaminergic activation. Slow onset, 12-15 hour half-life, little euphoria, low (but not zero) abuse potential.
• Amphetamine type: active release of dopamine and noradrenaline from vesicles. Fast onset, pronounced euphoria, clear rebound as it wears off, high abuse potential.
• Practical consequence: modafinil is harder to steer at the back end (a long half-life cannot be taken back), but comes without the evening crash.

After oral dosing the peak plasma level is reached after 2 to 4 hours, steady state within 2 to 4 days. The elimination half-life is 12 to 15 hours (Robertson & Hellriegel, Clinical Pharmacokinetics 2003). That is the practically most important figure of the entire substance.

Do the arithmetic once: a dose at 1pm still carries roughly half of its peak level at midnight. That is why practically every protocol lands on the same rule - dose early in the morning or not at all. Elimination runs mainly via amide hydrolysis in the liver, with under 10 percent excreted unchanged.

On wakefulness the evidence is strong. In the randomized multicenter trial of the US Modafinil in Narcolepsy Study Group (Annals of Neurology 1998, 283 participants), 200mg and 400mg daily improved every objective and subjective sleepiness measure versus placebo. Across 40 weeks of open-label continuation the effect held without tolerance developing - on discontinuation sleepiness simply returned to baseline, with no amphetamine-type withdrawal symptoms.

On cognitive improvement in rested healthy people the picture is considerably more sober. The meta-analysis by Roberts and colleagues (European Neuropsychopharmacology 2020) found a statistically significant but small overall effect across 14 modafinil studies (SMD 0.12), essentially carried by memory updating. The authors state explicitly that the widespread perception of a strong cognitive enhancer is not backed by the data. Short version: well documented against tiredness, weakly documented as an intelligence booster.

This is the most overlooked point with this substance. Modafinil induces CYP3A4/5. In the controlled study by Robertson and colleagues (Clinical Pharmacology & Therapeutics 2002) in 41 women on long-term combined oral contraceptives, ethinyl estradiol exposure measurably decreased under 200mg to 400mg modafinil over four weeks. The induction was predominantly gastrointestinal, which is why triazolam exposure fell considerably more.

Prescribing information therefore notes that hormonal contraception is less reliable during use and for about a month afterwards. In the other direction, modafinil inhibits CYP2C19, which concerns substances such as diazepam, omeprazole, propranolol or phenytoin.

• Serious skin reactions: rare but serious. Stevens-Johnson syndrome and toxic epidermal necrolysis are documented in registration data, mostly within the first one to five weeks. Any new rash, any blistering, any involvement of mouth, eyes or mucous membranes is a reason to stop and a case for medical assessment.
• Headache: most frequently documented effect, dose-dependent, mostly mild to moderate.
• Sleep disruption: almost always a question of timing, not of dose.
• Nausea, nervousness, reduced appetite, dry mouth: regularly reported in the trials.
• Circulation: mild increases in blood pressure and heart rate. Adds up with other sympathomimetic substances.
• Abuse potential: lower than with amphetamines, but not zero. The Volkow paper derives this directly from the dopamine increase in the nucleus accumbens.

Store dry, at room temperature and protected from light. Keep tablets in the original bottle, out of reach of children.